Originally published by our sister publication Specialty Pharmacy Continuum
By SPC News Staff
The FDA approved a citrate-free high-concentration formulation (HCF) of adalimumab-adaz (Hyrimoz, Sandoz) injection, a biosimilar to Humira (AbbVie).
The adalimumab citrate-free HCF (100 mg/mL) is approved to treat seven indications covered by the reference biologic, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease,